SUDA Licenses a Novel iNKT ( invariant Natural Killer T) Cell Therapy Platform from Imperial College London- SUDA obtains a global, exclusive Licence from Imperial College London for a novel invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment.
- Its a platform technology .The iNKT cell platform can be used in conjunction with multiple chimeric antigen receptors (CARs) to target blood cancers. iNKT cells are expected to be suitable for off-the-shelf dosing, as one healthy donor can supply cells to treat many patients.
- CAR-iNKT cells have been shown to outperform conventional CART cell therapies in preclinical studies.
Pre-clinical studies show that:
▪ CAR-iNKT cells work more efficiently than conventional cell therapies
▪ CAR-iNKT cells outperform CAR-T cells, rapidly clearing the cancer cells and increasing the number of surviving animals by 1.5x when the CD1d protein is on the surface of cancer cells.
▪ CAR-iNKT cells can result in a remission without additional treatment
▪ Additional CARs could be added to the iNKT cells, potentially enhancing their activity
In vivo anti-tumour activity of CAR19-iNKT after three days▪ Tumour cells expressing CD1d were intravenously delivered into mice
▪ Mice were treated with:
▪ Nothing (PBS)
▪ Unmodified T cells (T)
▪ Unmodified iNKT cells (iNKT)
▪ CAR19-T cells
▪ CAR19-iNKT cells
▪ After three days, all cancer cells in the iNKT treated mice were eradicated
▪ Cancer cells persisted with all other treatments
▪ CAR19-iNKT cells display swift action and memory-like effect
Extremely exciting results from animal models
CAR19-iNKT Cells: Superior Animal Survival After 90 days
After 90 days only mice treated with CAR19-T cells or CAR19-iNKT remained alive
1.5x more mice treated with CAR19-iNKT cells remained alive after 90 days relative to CAR19-T cells
As you can see from the results above , Overall survival of animal models was almost 100 % After 10 days
In vivo anti-tumour activity of CAR19- iNKT cells following relapse
▪ Tumour cells expressing CD1d were intravenously delivered into mice
▪ Four mice treated with CAR19-iNKT cells had the cancer return to the brain
▪
In all four mice, the cancer was eliminated a second time with no additional dosing▪ This provides evidence that CAR19- iNKT cells can survive and continue to protect against cancer cells in vivo
iNKT platform technology can also be potentially use to produce an ‘off-the-shelf’ product
iNKT cells have been shown to be protective against acute graft-versus host disease (GVHD).
As such, the therapy may be produced from a healthy donor and delivered to many patients, potentially resulting in a more effective product.
SUD is lead by Mr Paul Hopper , who is a serial achiever in Bio Medical Healthcare Sector
Mr. Hopper Founded IMU Mcap which is trading at 1.78 Billion Mcap
He Sold viralytics for 500 mil
He is a founder of PTX trading at 125 Mil Mcap
He is a founder of BioScience Oncology which was acquired by Scopus Biotech
He was a founder of Glioblast which was merged into KZA trading at 178 Mil Mcap
He is a founder of newly listed CHM trading at 97.6 Mil Mcap
And cheapest of all , Mr. Baker is the chairman of SUD trading at 10 Mil EV and I am extremely confident Mr. Hopper will lead SUD team to success with this new acquisition !
Some recent deals in this sector are attracting a lot of investments
Athenex to Acquired Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform for Total potential
consideration of $185 million, comprising $70 million upfront primarily in Athenex common stock, and $115 million in development milestones . Kurr is also an early stage iNKT cell therapy company
https://ir.athenex.com/news-releases/news-release-details/athenex-acquire-kuur-therapeutics-expand-cell-therapyAppia Bio raised $52 Million Series A Financing in MAY 2021 . Appia Bio is a pre clinical iNKT cell therapy platform company.
https://www.prnewswire.com/news-releases/appia-bio-launches-with-52-million-series-a-financing-and-establishes-scientific-advisory-board-301287685.htmlIMO this deal is a game changer for SUDA and its shareholders . I can understand the frustration of long-term investors of SUD and I must admit that I have also invested in SUD a year back and it has been a painful hold + the opportunity cost but I am extremely pleased with this deal and IMO this new deal will make our wait a worthwhile !
I will be a buyer in SUD under 5c ( 25 mil Mcap , 8 Mil Cash )
In medium term my realistic target for SUD is 20c ( 100 mil Mcap ) and In long term post completion of phase 1 , IMO it can get bluesky valuations !
Also please note it's not a one trick pony ,It's a platform tech and can generate pipeline of multiple programs !
Please DYOR
ALL IMO
Bhavdip
(20min delay)